Alto Neuroscience (ANRO) Shares Outstanding (Weighted Average) (2023 - 2026)

Alto Neuroscience has disclosed Shares Outstanding (Weighted Average) across 4 years of filings, most recently posting $32.9 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $32.9 million, up 21.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.9 million (up 21.61% YoY), and the FY2025 annual result was $28.9 million, up 17.28% from the prior year.
• Shares Outstanding (Weighted Average) came in at $32.9 million for Q1 2026 at Alto Neuroscience, up from $28.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $32.9 million in Q1 2026 to a low of $3.7 million in Q1 2023.
• The 4-year median for Shares Outstanding (Weighted Average) is $24.6 million (2024), against an average of $19.2 million.
• Across the five-year window, Shares Outstanding (Weighted Average) jumped 625.29% in 2024 and increased 0.54% in 2025, its largest moves.
• Alto Neuroscience's Shares Outstanding (Weighted Average) stood at $3.7 million in 2023, then soared by 559.39% to $24.6 million in 2024, then climbed by 17.28% to $28.9 million in 2025, then climbed by 14.01% to $32.9 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $32.9 million (Q1 2026), $28.9 million (Q4 2025), and $27.1 million (Q3 2025), per Business Quant data.